Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes

Juan F. Reyes1 · Christopher Sackmann1 · Alana Hoffmann2 · Per Svenningsson3 · Jürgen Winkler2 · Martin Ingelsson4 · Martin Hallbeck1

Received: 28 September 2018 / Revised: 3 April 2019 / Accepted: 3 April 2019 / Published online: 11 April 2019
© The Author(s) 2019

Abstract
The intercellular transfer of alpha-synuclein (α-syn) has been implicated in the progression of Parkinson’s disease (PD) and multiple system atrophy (MSA). The cellular mechanisms underlying this process are now beginning to be elucidated. In this study, we demonstrate that the gap junction protein connexin-32 (Cx32) is centrally involved in the preferential uptake of α-syn oligomeric assemblies (oα-syn) in neurons and oligodendrocytes. In vitro, we demonstrate a clear correlation between Cx32 expression and oα-syn uptake. Pharmacological and genetic strategies targeting Cx32 successfully blocked oα-syn uptake. In cellular and transgenic mice modeling PD and MSA, we observed significant upregulation of Cx32 which correlates with α-syn accumulation. Notably, we could also demonstrate a direct interaction between α-syn and Cx32 in two out of four human PD cases that was absent in all four age-matched controls. These data are suggestive of a link between Cx32 and PD pathophysiology. Collectively, our results provide compelling evidence for Cx32 as a novel target for therapeutic intervention in PD and related α-synucleinopathies.

Keywords Parkinson’s disease (PD) · Multiple system atrophy (MSA) · Alzheimer’s disease (AD) · Cell-to-cell transfer · Prion-like transfer · Gap junction proteins · Cx32 · GJB1 · alpha-Synuclein (α-syn)

Introduction
Parkinson’s disease (PD) is clinically characterized by the progressive decline of motor and non-motor functions [47]. The progressive accumulation of hallmark protein deposits comprised primarily of the alpha-synuclein protein (α-syn) is a signature lesion of PD and other neurodegenerative disorders which collectively are known as synucleinopathies [16]. These pathological conditions include dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), which, in addition to PD, are the most common synucleinopathies [57, 58]. Rare mutations (A30P, E46K, and A53T) or multiplications of the α-syn gene (SNCA) have been linked to autosomal dominant forms of PD that promote early disease onset [15, 24, 36]. In contrast to PD and DLB, where α-syn accumulation occurs predominantly in neurons, the accumulation of α-syn in cells of the oligodendrocyte lineage is the characteristic pathological feature of MSA [67]. While α-syn aggregation in neurons is limited in MSA, a widespread neuronal degeneration is still observed and may partly account for the progressive clinical symptoms that in some instances resemble those of PD [67]. To date, accumulating evidence has shown that pathological α-syn has the capacity to self-seed, aggregate, and propagate between cells in vitro and in animal models of PD and MSA [3, 10, 25, 27, 70]. While the molecular mechanisms underlying α-syn cell-to-cell transfer are only beginning.
to be understood, a direct neuroanatomical connection has been suggested to play a role [28, 35, 41, 42]. Moreover, the recent identification of two novel receptors specific for α-syn fibrils (LAG3 and FcγRIIB) [7, 29] has shed light on the potential existence of membrane receptors for α-syn oligomers, protein assemblies associated with neurotoxic properties and cellular propagation [20].

Direct cellular connectivity and communication are provided in part by dynamic multifunctional membrane structures termed gap junction channels (GJC). These structures are composed of two opposing hemichannels, each formed by the self-assembly of six transmembrane proteins termed connexins (Cx) [4]. In the human brain, 21 Cx genes have been shown to be translated into proteins that differentially interact to generate multiple GJC types (homomeric or heteromeric). As such, each GJC type acquires different functional properties that depend on the Cx proteins involved [5, 71]. Under normal physiological conditions, GJC and hemichannels play independent, and critical roles to maintain and promote intercellular homeostasis, allowing the direct transfer of ions and small molecules less than 1 kDa in size (e.g., sugars, amino acids, and nucleotides) between connecting cells [75]. However, dysregulation of Cx expression coupled with Cx-mediated uptake and transfer of unconventional proteins have been reported in multiple pathological conditions, including viral infections and neurodegenerative disorders [49]. For example, Cx dysregulation mediated by oligomeric amyloid-beta peptides (oAβ) associated with Alzheimer’s disease (AD) [33] as well as the viral transfer of thymidine kinase [61] and dickkopf-1 proteins from herpes simplex and human immunodeficiency viruses [32], respectively, has been described.

In the current study, we report the identification of Cx32 centrally involved in the selective uptake and propagation of α-syn oligomers (α-α-syn) in both neurons and oligodendrocytes, the primary cell types affected by α-syn aggregation in PD and MSA, respectively. Correspondingly, modulation of Cx32 protein turnover using pharmacological and genetic strategies demonstrates a clear association between Cx32 expression and oα-syn uptake. Moreover, we found that recipient cells overexpressing Cx32 more readily take up oα-syn from donor cells expressing α-syn-GFP relative to control cells expressing untagged mCherry proteins in a co-culture system [43]. By blocking Cx32 activity using either Cx32-specific peptide mimetics or selective gap junction inhibitors, we decreased α-syn uptake in a concentration-dependent manner. Furthermore, we found that exposure to oα-syn assemblies or expression of the α-syn gene (SNCA) promotes Cx32 upregulation. Consistent with our in vitro findings, we identified a significant upregulation of Cx32 in transgenic (Tg) animal models of PD (L61, A30P) and MSA (MBP29) overexpressing human α-syn in neurons or oligodendrocytes, respectively. Finally, we could demonstrate a direct interaction between α-syn and Cx32 in two out of four human PD cases that was absent in all four age-matched controls, suggesting a potential link between Cx32 and PD pathophysiology. Collectively, our results provide strong evidence for Cx32 centrally involved in the preferential uptake and propagation of oα-syn assemblies, pinpointing Cx32 as a novel therapeutic target to impede the uptake and spread of α-syn pathology in PD and related α-synucleinopathies.

Materials and methods

Generation of ATTO-labeled α-syn

Recombinant α-syn protein was purchased in a lyophilized form from Alexotech in a lyophilized form. To covalently label α-syn with ATTO-550 or ATTO-488 fluorescent tags, we used a protein:dye ratio of 1:2 as previously reported [45]. The protein solution was then mixed with reactive ATTO-550 dye freshly dissolved in DMSO (Sigma-Aldrich). Unreactive dye was removed by gel filtration chromatography using GE Sephadex G-25 (GE Healthcare), and labeled fractions were analyzed by Western blot analysis and size exclusion chromatography (SEC). Positive fractions were pooled, lyophilized, and then stored at −20 °C until further use.

Generation of α-syn and amyloid-beta (Aβ) assemblies

To generate different α-syn assemblies, we solubilized ATTO-labeled proteins in PBS to generate soluble monomers at a concentration of 4.0 mg/mL. We then separated α-syn monomers into three different fractions, each containing 350 μL of protein per tube, thereby ensuring the same concentration for all α-syn assemblies. The monomeric fraction was immediately stored at −80 °C until further use. To generate oligomers and fibrils, we incubated monomers at 37 °C for 5 days in an Eppendorf SS mini-shaker (Eppendorf) with constant shaking at either 350 or 1000 RPM, respectively. Assembled proteins were then aliquoted and stored at −80 °C until further use. To generate oAβ assemblies, we prepared recombinant Aβ peptide (1–42) as previously reported [55]. Briefly, recombinant Aβ1–42 peptides (Innovagen) were dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and vacuum-dried overnight. The next day, Aβ1–42 was diluted to a final concentration of 100 μM in HEPES (20 mM pH 7.4), vortexed, sonicated for 10 min, and incubated at 4 °C overnight to generate oligomeric assemblies.
Transmission electron microscopy (TEM) characterization of α-syn assemblies

α-syn monomers, oligomers, and fibrillar assemblies were prepared for TEM analysis as previously reported [45]. Briefly, each sample was placed on carbon-coated 200-mesh grids, negatively stained with 1% uranyl acetate, and analyzed with a Jeol 1400 transmission electron microscope (Jeol). Images were taken using a Gatan Orius CCD camera (Gatan).

Size exclusion chromatography (SEC)

SEC was performed to confirm protein assembly as previously reported [11]. Briefly, protein samples were loaded on a Superdex 75 10/300 GL column (GE Healthcare), and eluted protein fractions were measured using absorbance of 280 nm. For confirmation of ATTO-550 labeling, protein fractions were also analyzed at an absorbance of 550 nm.

Human-induced oligodendrocyte progenitor cells (OPC) differentiation

To differentiate human induced pluripotent stem cells derived OPCs (Tempo Biosciences) into mature, myelin-positive oligodendrocytes (MBP) we plated OPCs on matrigel (Corning) and incubated them with DMEM/F12 containing HEPES, glutamine (2 mM), nonessential amino acids (1X) (Life Tech), 1X StemPro Neural Supplement (Invitrogen), PDGF-AA (10 ng/mL, Cat: 100-13A, Peprotech), NT3, (10 ng/mL; Cat: 450-03, Peprotech), biotin (100 ng/mL, Sigma-Aldrich), and cAMP (5 µM, Sigma-Aldrich). Cell differentiation was induced for 30 days following incubation with 50:50 DMEM/F12:Neurobasal medium (Life Tech) containing nonessential amino acids 1X (Life Tech), 1X B27 (Life Tech), 2 l-glutamine (Life Tech), biotin (100 ng/mL, Sigma-Aldrich), brain-derived neurotrophic factor (BDNF, 10 ng/mL; Cat: 450-02, Peprotech), ascorbic acid (20 µg/mL, Sigma-Aldrich), cAMP (1 µM, Sigma-Aldrich), and T3 (200 ng/mL, Sigma-Aldrich).

Generation of SH-SY5Y, OLN-93, and OPC cell lines

Stable human SH-SY5Y, rat OLN-93 cell lines, and human OPC expressing proteins of interest were generated by transfection with plasmid vectors expressing either human Cx32-mCherry (a gift from Michael Davidson, Addgene plasmid # 55022), Cx43–IREs–GFP (a gift from Trond Aasen, Addgene plasmid # 65433), Cx43-HA (a gift from Robin Shaw, Addgene plasmid # 49851), mCherry (a gift from Michael Davidson, Addgene plasmid # 54517), and α-syn-GFP using an empty GFP plasmid vector (a gift from Didier Trono, Addgene plasmid # 12258) according to the manufacturer’s instructions (Amaxa Nucleofector, Lonza). To generate Cx32-KO cell lines, we nucleofected cells (Amaxa Nucleofector, Lonza) with commercially available gRNA plasmid sequences (Santa Cruz Biotechnology, Cat# 2234) or self-generated sequences containing a fluorescent reporter. When applicable, transfected cells were selected with appropriate antibiotics (G418, Sigma-Aldrich) followed by single cell sorting using FACS into 96-well plates to generate clonal cell lines.

HEK-293 transfection and α-syn treatment

HEK-293 cells were seeded in a 6-well plate at 90% confluency prior to transfection. The next day, we transfected the cells with either Cx32 or Cx43 plasmids (as above) using Lipofectamine® LTX reagents according to the manufacturer’s instructions (Life Technologies) with increasing concentrations of plasmid DNA constructs (15 and 50 µg, respectively). Briefly, 1 h prior to transfection, proliferation medium (MEM with serum) was removed and replaced with MEM containing glutamine and 1% penicillin/streptomycin without FBS. Subsequently, the growth medium was removed and replaced with MEM containing plasmid DNA and transfection reagents. The next day, cells were trypsinized and transferred to a 12-well plate for α-syn uptake analysis. Cells were then allowed to attach prior to treatment with different α-syn assemblies (1 µM) in serum free MEM medium (with glutamine and 1% penicillin/streptomycin) for 24 h. Cells were then washed three times in PBS, trypsinized and pelleted by centrifugation at 13,000 RPM for 5 min on a

\[\text{Springer}\]
benchtop centrifuge (Eppendorf) then prepared for Western blot analysis.

**Primary neuron isolation**

Primary cortical neurons were obtained from mouse cortices on embryonic day 16 [8]. In brief, cortices were dissected, and neurons were seeded onto 12-well culture dishes at $3 \times 10^5$ cells/well in Neurobasal media (Life Technologies) supplemented with penicillin (5 U/mL), streptomycin (5 g/mL), B27 supplement, and glutamine.

**Pharmacological gap junction inhibition and peptide mimetic treatments**

To pharmacologically inhibit gap junction proteins, we treated differentiated SH-SY5Y cells, primary neurons (DIV 10) and differentiated OLN-93 oligodendrocytes for 24 h in the presence of increasing concentrations of CBX (50, 100 µM), MQ (25, 50 µM), 2-APB (100 or 200 µM, Sigma-Aldrich) or the synthetic peptide mimetics Gap3211, Gap2409, and Gap2605 (100, 200 µM, Alpha Diagnostic International) in the presence of 1 µM ATTO-550 labeled α-syn assemblies (oligomers of fibrils) for 24 h in MEM with glutamine and 1% penicillin/streptomycin without FBS (Life Technologies). Following pharmacological or peptide mimetic treatment, cells were washed three times with PBS followed by fixation with 4% paraformaldehyde (PFA) for 20 min. Cells were then washed and prepared for immunocytochemistry.

**Inhibition of the p38 MAPK pathway**

To inhibit or activate the p38 MAPK pathway, we treated differentiated human SH-SY5Y cells expressing α-syn-GFP with increasing concentrations of the MAPK inhibitor SB203580 (10 and 25 µM) or anisomycin (1, 3, and 5 µM, cell-signaling technology), respectively, in the presence of MEM (without FBS) containing α-syn oligomers (1 µM) for 24 h at 37 °C. Following treatment, cells were washed three times with PBS followed by fixation with 4% paraformaldehyde (PFA) for 20 min. Cells were then washed and prepared for immunocytochemistry.

**Cellular energy assessment analysis**

To assess whether Cx32-mediated uptake is an energy-dependent mechanism, we treated differentiated Cx32-mCherry- or mCherry-expressing cells with 1 µM α-syn. Following protein treatment, we incubated cells at either 37 °C or 4 °C for 6 h. Cells were then washed with PBS and subjected to Western blot analysis.

**Immunocytochemistry and immunohistochemistry**

Differentiated SH-SY5Y cells, primary neurons, and differentiated OLN-93 cells were processed for immunocytochemistry as previously reported [45]. Briefly, cells fixed with 4% PFA were washed three times with PBS and permeabilized by incubation in 0.1% Triton X-100 in PBS for 30 min on ice. Next, cells were washed with PBS and incubated in 5% BSA for 1 h at room temperature, followed by incubation with primary antibodies overnight at 4 °C (Suppl. Table S1, Online Resource 1). The next day, we washed the cells with PBS and incubated them with respective fluorescently labeled secondary antibodies for 1 h (goat antimouse or goat anti-rabbit IgG Alexa Fluor 488, 564 or 633, Life Technologies), followed by Hoechst staining (Sigma-Aldrich). For immunohistochemistry, paraffin-embedded tissue sections were rehydrated in xylene (Sigma-Aldrich) followed by incubation in decreasing concentrations of ethanol (100, 95, 70, and 50%) then rinsed in water for 10 min. Epitope retrieval was then performed using acidic conditions according to the manufacturer’s instructions (Dako). Tissue sections were rinsed three times (5 min) with 0.04% Triton-X in PBS and processed for immunohistochemistry as described above.

**Confocal image analysis**

To visualize the fluorescence immunostaining, we used a Zeiss LSM 510 confocal microscope equipped with Ar and HeNe lasers to acquire Z-stacks of consecutive confocal images. For fluorescence measurements, all imaging parameters (e.g., laser power, exposure, and pinhole size) were held constant after microscope settings were established using appropriate controls. The results are provided as the relative fluorescent intensity of drug-treated samples compared to untreated controls.

**Brain homogenate sample preparation**

Mouse brain hemispheres from Tg animals overexpressing wild-type α-syn in neurons (Line 61) and wild-type littermate controls were purchased from QPS-neuro, Austria [46]. Brain samples from mice harboring mutant human α-syn proteins (A30P, Suppl. Table S2, Online Resource 2) were generated and obtained from Professor Philipp Kahle [23]. Frozen cortical regions were separated from hemispheres and then homogenized in RLT lysis buffer (Qiagen) on ice using a hand-held homogenizer (Polytron, PT 2100, Kinematica AG). We then briefly sonicated (SoniPrep 150) samples to eliminate non-homogenized clumps and centrifuged them at 1000 RPM for 5 min. The supernatant was collected and quantified using Nanodrop (Saveen and Werner), and prepared for Western blot analysis and qRT-PCR.
For human brain samples (Suppl. Table S3, Online Resource 3), frozen tissue sections from the putamen or SNpc isolated from controls or PD cases were obtained from Karolinska Institute (KI) and processed as described above. The MSA mouse model (MBP29-hα-syn mice, hereafter: MBP29 mice) was obtained from Professor Eliezer Masliah [56]. All animals were treated according to the European Union (2010/63/EU) and NIH (National Institute of Health) guidelines for the humane treatment of animals. Cohorts were maintained under standard animal housing conditions with a 12 h dark–light cycle and free access to food and water. Mice were euthanized under anesthesia and transcardially perfused with 0.9% sodium chloride solution. Cortices and corpora callosa were then microdissected and homogenized using QIAzol Lysis Reagent (Qiagen) for tissue homogenization containing proteinase and phosphatase inhibitors. Sonication was performed on ice for 20 s and the supernatant was collected after centrifugation. The addition of chloroform was followed by centrifugation-induced phase separation. Samples were further diluted in radiolmmunoprecipitation assay (RIPA) buffer, and the protein concentration was measured using the Pierce™ BCA protein assay kit (Thermo Scientific). The human MSA samples and age as well as gender-matched controls (obtained from the Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam)—were also prepared as described above. RNA was purified using an RNeasy mini kit (Qiagen) according to the manufacturer’s instructions, and the concentration was determined using Nanodrop (Peqlab). The GoScript™ Reverse Transcription System (Promega) was used for cDNA generation, and gene transcription was quantified in a Light Cycler 480 (Roche) using Sso Fast EvaGreen Supermix (Bio-Rad).

**Western blot analysis**

Following exogenous protein treatment, cells were washed three times in PBS for 5 min and subsequently incubated with trypsin for 5–10 min until complete cellular detachment. Cells were then pelleted by centrifugation at 13,000 RPM (Eppendorf) and lysed in SDS-lysis buffer followed by a brief sonication to completely lyse cell pellets and determine protein concentration using DC Assay (Bio-Rad). All samples were then resuspended in a final concentration of 1X Laemmli’s sample buffer, boiled for 5 min, separated on 10% SDS-PAGE (CBS Scientific), and transferred to nitrocellulose membranes using iBLOT kits (Life Technologies). Non-specific protein binding was blocked by incubating membranes with 2% nonfat dry milk, followed by incubation with primary antibodies (Suppl. Table S1, Online Resource 1) at 4 °C overnight. After rinsing the membranes using Tris-buffered saline (Life Technologies), we incubated them with peroxidase-conjugated goat anti-mouse or anti-rabbit IgG H + L secondary antibodies (Dako) for 1 h at room temperature, followed by ECL substrate (Bio-Rad) to visualize the signal on a ChemiDoc XRS+ (Bio-Rad). Densitometric analysis was performed using ImageJ (Fiji), and values with arbitrary units were normalized to the signals obtained from total protein measured with either GAPDH or β-actin (Suppl. Table S1, Online Resource 1). For MSA samples, proteins were resuspended in a final concentration of 1X NuPAGE™ LDS Sample buffer (Thermo Scientific) and 1X NuPAGE™ Sample Reducing Agent, heated for 10 min at 70 °C and separated on NuPAGE™ 4–12% Bis–Tris Protein Gels (Thermo Scientific). Afterwards, proteins were transferred to an EMD Millipore Immobilon™-FL PVDF Transfer Membrane (Millipore). Non-specific protein binding was blocked by incubating membranes with 1% BSA in Tris-buffered saline supplemented with 1% Tween-20 (TBS-T). The primary antibody was diluted in blocking buffer and incubated at 4 °C overnight. The next day, membranes were washed three times in TBS-T and incubated with the secondary antibodies donkey anti-mouse or donkey anti-rabbit diluted in blocking buffer for 1 h at room temperature. Membranes were washed three times with TBS-T and completely dried. Fluorescent signals were detected using FusionFX (Peqlab). Densitometric analysis of specific bands was performed using Bio-1D software (Vilber Lourmat), and values with arbitrary units were normalized to the signal obtained from total protein measured with β-actin.

**Immunoprecipitation of α-syn**

α-syn proteins were precipitated according to a previous report [60]. Briefly, cell lysates or frozen brain tissue blocks from controls and PD cases were homogenized in lysis buffer containing 20 mM Tris–HCl (pH 7.9), 137 mM NaCl, 5 mM Na2 EDTA, 1 mM EGTA, 10% glycerol, and 1% Triton X-100 with protease and phosphatase inhibitors (Roche). For cell lysates, 500 µg and 2 mg of human brain extract were incubated with 1 µg and 4 µg of antibody, respectively, overnight at 4 °C. A 1:1 suspension of Protein A/G agarose beads was added (Thermo Scientific), and the mixture was incubated at 4 °C for 4 h. The beads were then pelleted and washed thoroughly with cell lysate buffer according to the manufacturer’s instructions. Bound proteins were separated by SDS-PAGE followed by Western blot analysis.

**Co-culture conditions and FACS**

We co-cultured “donor” and “recipient” cells (1:1 ratio) under proliferating (T-25 flasks) or differentiating conditions (12-well plates) at 37 °C with 5% CO2 as previously reported [2, 43]. After trypsinization, the cells were washed three times in PBS and passed through a 40-µm filter prior to flow cytometry analysis. To block cellular connectivity, we co-cultured donor and recipient cells as above (1:1) in
Results

Cx32 facilitates the uptake of \( \alpha \)-syn assemblies in vitro

To determine whether connexins play a role in the uptake of different \( \alpha \)-syn assemblies, we first generated recombinant \( \alpha \)-syn monomers, oligomers (oo-syn), and fibrillar assemblies fluorescently tagged with ATTO-550 [45]. We then characterized soluble protein assemblies by size exclusion chromatography (SEC) as previously reported (Fig. 1a, b) [45]. As expected, we observed prolonged retention values for oo-syn assemblies compared to \( \alpha \)-syn monomers. The absence of free dye within our preparations was corroborated by measuring the absorbance of ATTO-550 (550 nm) using SEC (Fig. 1c). We next characterized all protein assemblies by transmission electron microscopy (TEM) and concomitant to the prolonged SEC retention values observed, the characteristic donut-like and filament ultrastructures typical of oo-syn and fibrillar assemblies, respectively, were observed.

**Confocal image analysis of FACS-sorted cells**

Co-cultured cells were loaded on a FACS Aria III with DIVA software (BD Biosciences) and double-positive cells were plated onto poly-L-lysine (Thermo Scientific) coated glass microscope chamber slides (Lab-tek), and allowed to attach overnight. We then fixed the cells in 4% PFA for 15 min at room temperature, washed them three times with PBS, permeabilized with 0.01% Triton X-100, and stained for Hoechst (Sigma-Aldrich). Cells were analyzed with a Zeiss LSM 510 confocal microscope equipped with Ar and HeNe lasers. Protein colocalization was analyzed by calculating the Pearson correlation coefficient from confocal images using Huygens Pro software (Hilversum, Netherlands).

**Semi-quantitative real-time PCR (qRT-PCR)**

RNA was extracted from cell and tissue samples using RNeasy Mini Kits according to the manufacturer’s instructions (Qiagen). cDNA was generated from RNA using a High-Capacity RNA to cDNA Kit (Applied Biosystems). Each RT-PCR reaction utilized 25 ng cDNA and was analyzed in technical duplicates or triplicates. Reactions were analyzed on a 7500 Fast Real-Time PCR System (Applied Biosystems). All primer/probes used in this study utilized the FAM–MGB TaqMan system and were purchased from Applied Biosystems or were generated using the primer design tool Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast) (Suppl. Table S1, Online Resource 1).

**Statistical analyses**

Every reported \( n \) is the number of biologically independent replicates. Except when noted otherwise, statistical analyses were performed using a one or two-way ANOVA with Tukey’s test when comparing multiple samples and genotypes and a two-tailed, unpaired Student’s \( t \) test when comparing two genotypes. Data distribution was assumed to be normal, but this was not formally tested. For Western blot analyses, band intensities were quantified using ImageJ software (Fiji) or Bio-1D (Vilber Lourmat) software, and values with arbitrary units were normalized to the signal obtained from the protein loading control. In each data group, the results are expressed as the mean ± SEM. For semi-quantitative RT-PCR, statistics were calculated using \( 2^{ΔΔCt} \) values, using One-way ANOVA with Tukey analysis for multiple comparisons. All data analyses were performed with GraphPad Prism 7.0 (La Jolla, CA). Findings were regarded as significant when * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \), **** \( p < 0.0001 \).
identified (Fig. 1d–f and Suppl. Figure S1a, b, Online Resource 4) [45]. We next analyzed the fibril length by TEM and observed an average length of 133.74 nm ± 3.53 nm, a result consistent with the length of non-sonicated α-syn fibrils (Suppl. Figure S1c, Online Resource 4) [44]. Following protein characterization, we transiently transfected human embryonic kidney cells (HEK-293) with increasing concentrations of the neuronal, non-canonically expressed Cx32 or the non-neuronally associated Cx43 (fused to mCherry and GFP, respectively), to exclude a general Cx effect. As expected, increased concentration of plasmid DNA transfection (15 µg; low and 50 µg; high) enhanced Cx expression in HEK-293 cells as shown by the increased intensity of the fluorescent tags observed under confocal microscopy and densitometry analysis (Fig. 1g and Suppl. Figure S1d, Online Resource 4). Consistent with the previous observations [40], the addition of fluorescent tags had no effect on Cx activity, gap junction formation or
Cx32 expression correlates with αsyn uptake. a Densitometric analysis of Cx32 protein levels in differentiated SH-SY5Y cells exposed to SB203580 for 24 h (10 and 25 µM), (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(2, 12)} = 5.547, *p < 0.05). b qRT-PCR analysis of Cx32 mRNA in differentiated SH-SY5Y cells with increasing SB203580 concentrations and untreated cells as controls (n = 3, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(2, 12)} = 4.562, *p < 0.05). d Representative Western blots showing Cx32, αsyn and GAPDH protein levels following SB203580 treatment. e Densitometric analysis of Cx32 protein expression in differentiated SH-SY5Y cells exposed to anisomycin for 24 h, (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(3, 11)} = 4.553, *p < 0.05). f qRT-PCR analysis of Cx32 mRNA in differentiated SH-SY5Y cells treated with increasing anisomycin concentrations and untreated cells as controls (n = 3, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(3, 8)} = 3.998, *p < 0.05). g Densitometric analysis of αsyn uptake following anisomycin treatment for 24 h (n = 4, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(3, 12)} = 5.327, *p < 0.05). h Representative Western blots showing Cx32, αsyn and GAPDH protein levels following anisomycin treatment. i j Western blot analysis of αsyn uptake in SH-SY5Y cells expressing Cx32-mCherry (n = 6) or mCherry (n = 4) incubated at 37 °C or 4 °C (one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s.; no significance, F_{(2, 10)} = 83.02, ***p < 0.001, ****p < 0.0001). k Densitometric analysis of Western blots of αβ uptake in differentiated SH-SY5Y cells expressing mCherry or Cx32-mCherry (n = 4, unpaired, two-tailed t test, t_{9} = 8.493, ***p = 0.0001). m Confocal image analysis of differentiated SH-SY5Y cells expressing mCherry or Cx32-mCherry (red) labeled with Alexa Fluor 647 (green) and then stained with Hoechst 33342 (blue); scale bar represents 200 µm. n Fluorescence intensity quantification of αβ uptake in differentiated SH-SY5Y cells expressing mCherry or Cx32-mCherry by confocal microscopy (n = 3 independent experiments and each representing the average of three different measurements, unpaired, two-tailed t test, t_{9} = 11.86 ***p < 0.001).

Membrane compartmentalization, as shown by the subcellular localization of Cx32-mCherry or Cx43-GFP at the cellular membrane (Suppl. Figure S1e, f, Online Resource 4). Interestingly, treatment of Cx-expressing cells with αsyn monomers, oligomers, or fibrillar assemblies demonstrated a selective increase in the uptake of αsyn that was Cx32-dependent (Fig. 1h, i). In contrast, HEK-293 cells expressing Cx43 showed no differences in protein uptake regardless of the assembly state of the αsyn molecule (Fig. 1h, i). Moreover, the increased levels of Cx32 in high-expression cells further amplified αsyn uptake, suggesting a correlation between Cx32 expression and αsyn uptake (Suppl. Figure S1d, g, Online Resource 4).

To verify that Cx32-mediated αsyn uptake was not due to differential expression in HEK-293 cells but a Cx32-dependent mechanism, we generated multiple clonal SH-SY5Y cell lines expressing Cx32 (Cx32-mCherry) or its heteromeric gap junction binding partner Cx26 (Cx26-mCherry) [59]. We also generated clonal cell lines expressing Cx43 (Cx43-HA) as well as untagged mCherry proteins alone to use as controls. The contribution of Cx32 to αsyn uptake was further tested by deletion of the Cx32 gene (GJB1) using CRISPR/Cas9 (Cx32-KO). Following SH-SY5Y differentiation to generate a neuron-like phenotype with morphological and biochemical characteristics of mature neurons [2, 73], we observed Cx32 expression localized to the cellular membrane. We next incubated SH-SY5Y cells with αsyn monomers, oligomers or fibrillar assemblies for 24 h. Consistent with the HEK-293 results (Fig. 1h, i), expression of Cx32 in differentiated neuronal SH-SY5Y cells selectively increased the uptake of αsyn as analyzed by Western blot and immunocytochemistry (Fig. 1j–l) when compared to αsyn monomers (Suppl. Figure S1h, Online Resource 4) and fibrillar assemblies (Fig. 1m, n). Consistent with the involvement of Cx32 in αsyn uptake, CRISPR/Cas9-based deletion of the Cx32-mCherry construct significantly blocked αsyn uptake, validating the involvement of Cx32 in the uptake of αsyn assemblies (Suppl. Figure S1i, Online Resource 4). As expected, overexpression of Cx26 or Cx43 in differentiated SH-SY5Y cells showed no differences in the uptake of any αsyn assemblies, corroborating a Cx32-dependent mechanism in the selective uptake of αsyn assemblies (Fig. 1j–n).

The mitogen-activated protein kinase (MAPK) pathway modulates αsyn uptake via Cx32

To further demonstrate a direct link between Cx32 expression and αsyn uptake in differentiated human neuronal SH-SY5Y cells, we investigated the impact of inhibiting the p38 MAPK pathway, which negatively regulates Cx32 protein turnover, on αsyn uptake [39]. We incubated differentiated SH-SY5Y cells with the potent p38 MAPK inhibitor SB203580 (10 and 25 µM), together with αsyn for 24 h. As expected, we observed a concentration-dependent increase in Cx32 protein expression and this effect led to a decrease in Cx32 mRNA (Fig. 2a, b). Correspondingly, the increase in Cx32 protein expression induced by SB203580 treatment correlated with a significant increase in αsyn uptake that was concentration dependent (Fig. 2c, d). In contrast, cells exposed to the p38 MAPK activator anisomycin (1, 3, and 5 µM), which promotes Cx32 degradation [39], showed a significant decrease in Cx32 protein expression and promoted a significant upregulation of Cx32 mRNA (Fig. 2e, f). Concomitant with the results above, the observed reduction in Cx32 expression correlated with a significant decrease in αsyn uptake, emphasizing a direct link between Cx32 expression and αsyn uptake (Fig. 2g, h).
Cx32 interacts with α-syn and facilitates uptake and transfer in neurons and oligodendrocytes. a Schematic representation of the co-culture donor and recipient SH-SY5Y models designed to quantify α-syn-GFP transfer as donor cells (green) and recipient cells shown in red by open (Cx32-mCherry) or closed circle (mCherry), depicting the relative expression of the plasmids. b Flow cytometry measurement of α-syn-GFP transfer in undifferentiated conditions (n = 9 independent experiments and each representing the average of triplicate measurements, unpaired, two-tailed t test, t(9) = 2.35, *p < 0.031). c Flow cytometry analysis of α-syn-GFP transfer in a differentiated state (n = 6 independent experiments and each representing the average of duplicate measurements, unpaired, two-tailed t test, t(9) = 4.03, ***p < 0.001). d Confocal image analysis of recipient cells (mCherry and Cx32-mCherry) containing α-syn-GFP oligomers sorted by FACS and analyzed by Huygens Pro (top 3D insert), demonstrating colocalization between Cx32 and α-syn-GFP as indicated by the Pearson correlation coefficient (P) of 0.79 compared to -0.13 for α-syn-GFP and mCherry; scale bars represent 20 µm. e Immunoprecipitation (IP) of α-syn followed by Western blot analysis with mCherry and α-syn antibodies identifies an interaction between α-syn and Cx32 f Densitometric analysis of g representative Western blots of α-syn uptake in monomeric, oligomeric or fibrillar assemblies in differentiated WT rat oligodendrocytes (OLN-93) or oligodendrocytes expressing Cx32-mCherry or cells lacking Cx32 (Cx32-KO) (n = 6, two-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, F(2, 28) = 6.13, *p < 0.05, **p < 0.01 ***p < 0.001). h Immunocytochemistry of OLN-93 cells overexpressing Cx32-mCherry showing the typical Cx32-mCherry plaques at the cell membrane (red, arrowheads), or cell soma (*) co-labeled with Cx32 antibody (green) and Hoechst (blue), scale bars represent 10 µm. Top insert represents a 3D image demonstrating the Cx32 plaque at the cellular membrane (arrow) and cytoplasm (*) i Immunocytochemistry and orthogonal view of human oligodendrocyte precursor cells (OPCs) overexpressing Cx32-mCherry (at the cell membrane, arrowheads) stained with Hoechst (blue) and CNPase (gray); scale bars represent 10 µm. j Densitometric analysis of k representative Western blot of α-syn uptake (monomeric, oligomeric or fibrillar) in differentiated human WT oligodendrocytes or oligodendrocytes overexpressing Cx32-mCherry (n = 4, two-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, F(4, 15) = 5.914, *p < 0.05, **p < 0.01)
**α-Syn binds and colocalizes with Cx32 during cellular uptake**

To validate α-syn transfer to recipient cells during our coculture conditions, we sorted double-labeled cells expressing either Cx32-mCherry or mCherry containing α-syn-GFP puncta using fluorescence-activated cell sorting (FACS). Using confocal microscopy, we visualized the presence of α-syn-GFP puncta within the cell soma and around the cell membrane of both Cx32-mCherry and mCherry recipient cells (Fig. 3d, Suppl. Figure S2d, Online Resource 5). We then evaluated the extent of colocalization between α-syn-GFP and Cx32-mCherry fluorophores or α-syn-GFP and mCherry by calculating the Pearson correlation coefficient.
Cx32 interacts with α-syn and facilitates uptake in oligodendrocytes

We next determined whether Cx32 also plays a role in the uptake of α-syn in oligodendrocytes, the cell type associated with canonical Cx32 expression in the central nervous system [40]. Using the rat oligodendrocyte cell line OLN-93 [45], we generated Cx32-KO cells using CRISPR/Cas9 or overexpressed Cx32-mCherry. We then differentiated these cells by serum deprivation as previously reported [45], followed by incubation for 24 h with α-syn monomers, oligomers or fibrillar assemblies. Consistent with our Cx32 neuronal model system, we observed a significant increase in the uptake of α-syn assemblies compared to monomers and fibrillar assemblies in Cx32-mCherry OLN-93 cells (Fig. 3f, g). Moreover, OLN-93 cells lacking Cx32 (Cx32-KO) showed a decrease in α-syn uptake compared to control conditions and although this was not statistically significant, it validates the involvement of other cellular mechanisms in this process (Fig. 3f, g). It is worth noting that whereas Cx32 in SH-SY5Y cells was observed at the cellular membrane (Fig. 11), Cx32-mCherry in OLN-93 oligodendrocytes localized primarily to the cell soma (Fig. 3h, asterisk). However, in some instances, we found that Cx32 was properly localized to the cellular membrane, forming the typical Cx32 plaques (Fig. 3h, arrowheads).

To further validate the involvement of Cx32 in the uptake of α-syn in oligodendrocytes, we transfected human oligodendrocyte precursor cells (OPCs) derived from induced pluripotent stem cells (iPSC) with Cx32-mCherry or untagged mCherry proteins. We observed Cx32-mCherry in differentiated human OPCs (2′,3′-Cyclic-nucleotide 3′-phosphodiesterase, CNPase+) localized to the cellular membrane, where it remained throughout the differentiation process (Fig. 3i). In contrast, untagged mCherry expression was observed throughout the entire cytoplasm (data not shown). We next differentiated OPCs for 30 days and used the expression of the myelin basic protein (MBP) by immunocytochemistry as a marker for cell maturity (Suppl. Figure S3b, Online Resource 6). Subsequently, we incubated differentiated OPCs with α-syn monomers, oligomers or fibrillar assemblies for 24 h. Using Western blot analysis, we found that expression of Cx32-mCherry in differentiated oligodendrocytes (MBP+) significantly increased the uptake of α-syn assemblies compared to monomeric or fibrillar assemblies (Fig. 3j, k). To validate a direct interaction between α-syn and Cx32 in human oligodendrocytes, we next treated differentiated OPCs (CNPase+) overexpressing Cx32-mCherry with ATTO-488-labeled α-syn for 24 h. Similar to the results in our neuronal culture model, we observed a remarkable colocalization between Cx32 and α-syn-ATTO-488 proteins in human oligodendrocytes (Suppl. Figure S3c, Online Resource 6). We next treated OPCs expressing Cx32-mCherry cells with α-syn followed by IP of α-syn as described above, and identified the presence of Cx32 within the immunoprecipitated samples by Western blot analysis (Suppl. Figure S3d, Online Resource 6). Collectively, our results confirm that Cx32 interacts with α-syn and facilitates its internalization in neurons and oligodendrocytes.

Cx32 peptide mimetic inhibitors reduce the uptake of α-syn assemblies

We next explored whether pharmacological strategies targeting Cx32 activity inhibit α-syn uptake. We exposed
differentiated wild-type SH-SY5Y cells to α-syn or fibrillar assemblies tagged with ATTO-550 [45], in the presence of specific Cx32 peptide mimic sequences (Gap3211 and Gap2409) known to bind and block Cx32 hemichannel activity [9, 13]. Gap3211 binds to the first extracellular loop [amino acid (AA) 52–63], whereas Gap2409 binds to the inner cytoplasmic transmembrane loop (AA100–110) of Cx32. Treatment of differentiated SH-SY5Y cells with α-syn assemblies in the presence of Gap3211 (Fig. 4a, b) or Gap2409 (Suppl. Figure S4a, c, Online Resource 7) for 24 h significantly reduced α-syn uptake. This treatment, however, had a limited effect on fibrillar α-syn uptake (Fig. 4a, Suppl. Figure S4a, e, Online Resource 7). Given the high sequence similarity of Cx32 between humans and rodents, we next exposed primary rat cortical neurons (DIV 10) to α-syn assemblies in the presence of Gap3211 or Gap2409. Consistent with our differentiated human neuronal SH-SY5Y results, we observed a significant reduction in α-syn uptake following Gap3211 or Gap2409 peptide mimetic treatment on primary neurons (Fig. 4c, d). Similarly, OLN-93 oligodendrocytes exposed to α-syn or fibrillar assemblies in the presence of Gap3211 or Gap2409 showed a marked decrease in α-syn uptake (Fig. 4e, f, Suppl. Figure S4b, d); however, this effect did not translate to fibrillar assemblies (Fig. 4e, f Suppl. Figure S4b, f, Online Resource 7).

To verify that inhibition of α-syn is dependent on the sequence of Cx32, we next treated differentiated human neuronal SH-SY5Y cells with Cx32 scrambled mimetic sequences (SC) of both GAP3211-SC (Suppl. Figure S5a, Online Resource 8) and 2409-SC (data not shown). In contrast to functional Cx32 sequences, we observed no inhibition of α-syn or fibrillar uptake using Cx32-SC (Suppl. Figure S5a, Online Resource 8). We next assessed whether functional mimetic sequences targeting Cx43 blocked α-syn or fibrillar uptake. We treated cells with peptides targeting the first extracellular loop of Cx43 (Gap2605, AA64–76), but no effect on oligomeric or fibrillar α-syn assemblies could be detected (Suppl. Figure S5b, Online Resource 8). These results indicate that blockade of Cx32 using peptide mimetic sequences partially impedes the uptake of α-syn, but this treatment has limited effect on fibrillar α-syn assemblies.

Pharmacological gap junction inhibitors reduce α-syn uptake

To further assess the potential of Cx32 as a suitable target for pharmacological intervention to block α-syn uptake, we next tested the widely used pan-connexin gap junction inhibitor carbenoxolone (CBX) [21]. Treatment of differentiated neuronal SH-SY5Y cells with increasing concentrations of CBX (50 and 100 µM) significantly blocked α-syn and fibrillar uptake in a concentration-dependent manner (Suppl. Figure S6a, b, Online Resource 9). Similarly, treatment of oligodendrocytes (OLN-93) with CBX led to a significant decrease in α-syn and fibrillar uptake that was concentration dependent (Suppl. Figure S6c, d, Online Resource 9). Given the non-specific inhibitory profile of CBX to different Cx proteins, we next assessed the effect of mefloquine (MQ), a selective inhibitor that targets gap junctions composed primarily of Cx26, Cx32 and/or Cx43 [21]. In our culture conditions, MQ (25 and 50 µM) significantly blocked the uptake of α-syn and fibrillar assemblies in human differentiated SH-SY5Y neuronal cells, primary cortical neurons (DIV 10) and differentiated OLN-93 oligodendrocytes in a concentration-dependent manner (Suppl. Figure S7a–f, Online Resource 10). Finally, we tested the inhibitory effect of 2-aminoethoxydiphenyl borate (2-APB), a highly selective gap junction inhibitor known to primarily target Cx26 and Cx32 [63]. Treatment of cells with 2-APB (100 and 200 µM) significantly blocked the uptake of α-syn and fibrillar assemblies in human SH-SY5Y neuronal cells (Fig. 5a, b), primary cortical neurons (DIV 10) (Fig. 5c, d) and OLN-93 oligodendrocytes in a concentration-dependent manner (Fig. 5e, f).

α-Syn expression differentially regulates Cx32 in neurons and oligodendrocytes

Having established that Cx32 expression preferentially modulates α-syn uptake in neurons and oligodendrocytes, we next assessed the effect of α-syn uptake in differentiated SH-SY5Y cells overexpressing human α-syn-GFP, a useful cellular system to model PD in vitro [26]. We treated differentiated SH-SY5Y cells overexpressing human α-syn-GFP with exogenously generated α-syn assemblies for 24 h, then measured protein uptake by Western blot analysis. We observed a significant increase in the uptake of α-syn in cells expressing α-syn-GFP compared to controls (Fig. 6a). Importantly, this effect was not due to the proteolytic degradation of the endogenous α-syn-GFP construct, which remained fully intact (~40 kDa) throughout the experiment (Suppl. Figure S8a, Online Resource 11). Prompted by the observed increase in α-syn uptake in our in vitro cellular model of PD, we next examined the levels of Cx32 protein and mRNA before and after α-syn treatment. We found that Cx32 protein levels increased upon expression of α-syn-GFP compared to controls (Fig. 6b), with no further detectable increase following exogenous α-syn treatment. However, an increase in Cx32 mRNA following exogenous α-syn treatment compared to that of the untreated α-syn-GFP cells was observed, an effect that was more pronounced in the treated α-syn-GFP expressing cells than in wild-type-treated controls (Fig. 6c).

Next, we investigated whether Cx32 upregulation correlates with the levels of α-syn expression. We, therefore,
separated SH-SY5Y cells expressing low and high levels of α-syn-GFP using FACS (Suppl. Figure S8b, Online Resource 11). We then induced neuronal differentiation as previously reported [2], and assessed the levels of Cx32 expression by Western blot and qRT-PCR. Interestingly, we identified an increase in Cx32 protein upregulation that associated with the levels of α-syn-GFP expression, both at the protein and mRNA level (Suppl. Figure S8c, d, Online Resource 11), demonstrating a direct correlation between Cx32 upregulation and α-syn expression. (Suppl. Figure S8e, Online Resource 11). Collectively, our results suggest that expression of human α-syn or exposure to α-syn...
a. α-syn expression increases α-syn uptake

b. α-syn expression increases Cx32

c. α-syn increases Cx32 mRNA

d. α-syn differentially regulates Cx32 in OPCs

e. α-syn reduces Cx32 in OPCs

f. Cx32 levels in the L61 PD mouse model

h. Cx32 co-localizes with α-syn in neurons and oligodendrocytes in A30P Tg mice

g. Cx32 levels in the A30P PD mouse model
Human α-syn expression promotes Cx32 upregulation in vitro and in vivo in animal models of PD. a Densitometric analysis of α-syn oligomer uptake in control SH-SY5Y cells (n = 3) or cells expressing α-syn-GFP (n = 8) followed by Tukey's post hoc test for multiple comparisons, n.s. no significance, F(1, 18) = 12.33, ***p < 0.001. **p < 0.01, ***p < 0.001). b Protein analysis of Cx32 expression in control and α-syn-GFP-expressing cells before and after α-syn treatment (n = 3, one-way ANOVA followed by Tukey's post hoc test for multiple comparisons, n.s. no significance, F(1, 8) = 70.33, ****p < 0.0001). c mRNA analysis of Cx32 in control and α-syn-GFP-expressing cells before and after α-syn treatment (n = 3, one-way ANOVA followed by Tukey's post hoc test for multiple comparisons, F(1, 8) = 54.24, ***p < 0.001, ****p < 0.0001). d Densitometric analysis of Western blot of control WT OPCs (n = 8) and OPCs exposed to α-syn assemblies (n = 10) or OPCs expressing α-syn-GFP with or without α-syn treatment (n = 3 and 5, respectively, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s. no significance, F(2, 22) = 14.94, **p < 0.01, ***p < 0.001, ****p < 0.0001). e Densitometric analysis of OPCs expressing Cx32-mCherry exposed to α-syn assemblies (n = 7, unpaired, two-tailed t test, t8 = 5.836, ***p < 0.0001). f Densitometric analysis of wild-type (non-Tg) and transgenic (L61) mice overexpressing human wild-type α-syn (Mann–Whitney U = 2, n1 = 5, p > 0.05) or g α-syn harboring the familial A30P mutation (Mann–Whitney U = 1, n1 = 6, *p < 0.05). Schematic representations within the figures show the location of the brain region selected for analysis. h Immunohistochemistry of A30P mouse tissue sections co-labeled with the Cx32 antibody and human pan-specific α-syn antibody shows colocalization between α-syn and Cx32 in oligodendrocytes (I–III, *), between Cx32 and the neuron-specific β3-tubulin antibody (IV–VI, *) or between Cx32 and the phospho-specific pS129-specific α-syn antibody (VII–XII). The boxed area shows a high magnification of VII–IX (X–XII). Scale bars represent 20 μm assemblies promotes Cx32 upregulation in differentiated human neuronal SH-SY5Y cells.

We next investigated whether exogenous α-syn treatment or expression of α-syn-GFP in human oligodendrocytes would increase Cx32 expression. We exposed differentiated wild-type OPCs (CNPase+) to α-syn assemblies for 24 h then measured Cx32 protein expression. As expected, we observed a significant increase in Cx32 upregulation, albeit to a lesser extent than that observed in neuronal SH-SY5Y cells (Fig. 6d). However, in contrast to the neuronal SH-SY5Y model, we identified no differences in Cx32 protein expression between wild-type OPCs and OPCs overexpressing human α-syn-GFP (Fig. 6d). In fact, relative to wild-type OPC-treated cells, OPC-α-syn-GFP cells exposed to exogenous α-syn assemblies showed a significant decrease in Cx32 expression. However, although a trend for a reduction in Cx32 expression was observed following incubation of OPC’s expressing α-syn-GFP with α-syn assemblies compared to untreated α-syn-GFP cells, this effect was not statistically significant (Fig. 6d). We then asked whether OPCs overexpressing Cx32 would show a decrease in Cx32 following α-syn treatment. We incubated OPCs overexpressing Cx32-mCherry with α-syn proteins for 24 h then measured Cx32 protein levels by Western blot analysis. We observed a significant decrease in endogenous Cx32 protein expression in cells incubated with α-syn compared to untreated OPC-Cx32 cells (Fig. 6e). These results suggest that, compared to neuronal cells, human oligodendrocytes differentially regulate Cx32 expression following α-syn expression or exposure to α-syn assemblies.

α-Syn accumulation increases Cx32 in Tg models of PD and MSA

To assess a possible connection between α-syn and Cx32 in vivo, we analyzed adult and aged cortical brain homogenate samples from Tg mice overexpressing human wild-type α-syn (Line 61, 6 months) or mutant α-syn harboring the familial A30P mutation (18 months), both driven by the Thy-1 promoter (Suppl. Table S2 [23, 46], Online Resource 2). Compared to respective non-transgenic (non-Tg) age-matched controls, we observed a significant upregulation in Cx32 protein expression in L61 (Fig. 6f) and A30P Tg mice (Fig. 6g). The upregulation of monomeric Cx32 was corroborated using a different immunological probe targeting the C-terminal region of the Cx32 molecule (Suppl. Figure S8f, g, Online Resource 11). We then analyzed the levels of Cx32 mRNA in respective age-matched control mice and L61 and A30P cohorts. While we observed no statistically significant differences between non-Tg and Tg models (L61 and A30P), a trend of increased Cx32 mRNA levels in both PD models was noted (Suppl. Figure S8 h, Online Resource 11). To further assess whether Cx32 colocalizes with α-syn in situ, we performed immunohistochemistry on tissue sections from the A30P mice (Fig. 6h). We observed a clear colocalization between Cx32 and human A30P-α-syn that, in some instances, appeared within the membrane of cells of the oligodendrocyte lineage, as indicated by the morphological pattern of Cx32 labeling within oligodendrocytes (Fig. 6h, I–III). To further validate the presence of α-syn within cells of the oligodendrocyte lineage, we performed immunohistochemistry on adjacent tissue sections using the oligodendrocyte-specific marker CNPase and observed the presence of α-syn within CNPase+ cells [Suppl. Figure S9a (I–IV), Online Resource 12]. Moreover, we observed a clear colocalization between Cx32 and the neuronal-specific protein β3-tubulin, confirming the presence of Cx32 proteins within neuronal cell types (Fig. 6h, IV–VI). Finally, we immunolabeled tissue sections with a highly specific α-syn antibody that labels α-syn phosphorylated at serine 129 (pS129) and does not cross-react with a similar epitope in the neurofilament light chain protein (NFL [51]). Our qualitative observations revealed a clear colocalization between Cx32 and pS129 in neuronal cells (Fig. 6h, VII–XII) and oligodendrocytes co-labeled with CNPase and pS129 [Suppl. Figure S9a (V–VIII), Online Resource 12], corroborating the direct interaction between Cx32 and α-syn.
Fig. 7 α-syn promotes Cx32 upregulation in a mouse model of MSA (MBP29) and shows a direct interaction with Cx32 in human PD brains. a Densitometric analysis of a representative Western blot of Cx32 in young (3 weeks) non-Tg and Tg MBP29 cohorts from regions of the cortex and corpus callosum (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, $F_{(3, 16)} = 1.968$). Schematic representation within figure a shows the location of the brain region selected for analysis. b Densitometric analysis of d representative Western blot of Cx32 in adult (3 months) non-Tg and Tg MBP29 cohorts from regions of the cortex and corpus callosum (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, $F_{(3, 16)} = 8.991$, $p < 0.05$, $^{*}p < 0.01$). c Cx32 mRNA analysis (2$^{-\Delta \Delta C T}$) of young non-Tg (n = 5) and Tg MBP29 cohorts (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, $F_{(7, 32)} = 57.88$, $p < 0.05$, $****p < 0.0001$). f Cx32 mRNA analysis (2$^{-\Delta \Delta C T}$) of adult non-Tg (n = 5) and Tg MBP29 cohorts (n = 5, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons, n.s; no significance, $F_{(7, 32)} = 50.74$, $^{*}p < 0.05$, $^{*}^{{*}}p < 0.01$, $^{*}^{*}p < 0.0001$). g Densitometric analysis of Western blot of Cx32 in human brain homogenate samples from the putamen region of control (n = 4) and PD cases (n = 4, unpaired, two-tailed t test, n.s; no significance, $t_{6} = 1.56$). h Densitometric analysis of Western blot of Cx32 in human brain homogenate samples from the SNpc isolated from human PD cases (n = 4) and age-matched controls (n = 4, unpaired, two-tailed t test, $t_{6} = 2.753$, $p < 0.05$). i Densitometric analysis of Cx32 j from the cortex within the BR9 region of control and PD cases. k Representative Western blot of α-syn IP from the human putamen isolated from controls and PD cases demonstrates a direct interaction between Cx32 and human α-syn in PD (2 out of 4) cases but not in age-matched controls (n = 4). l Western blot analysis of Cx32 protein levels within the putamen of control (n = 5) or MSA cases (n = 5, unpaired, two-tailed t test, n.s; no significance, $t_{8} = 2.627$, $p < 0.05$)

in neuronal and oligodendrocyte cell types in the Tg A30P mouse model of PD.

We then investigated the relationship between Cx32 and α-syn in the MBP29 mouse model of MSA, which overexpresses human wild-type α-syn in oligodendrocytes driven by the MBP promoter [62]. We prepared brain homogenate samples from the cortex (ctx) and corpus callosum (cc) of young (3 weeks) and adult cohorts (3 months) followed by Western blot analysis. We observed no statistically significant differences in the Cx32 profile between young age-matched controls and Tg MBP29 mice (Fig. 7a, b). Importantly, and consistent with the accumulation of α-syn deposits within these mice over time, we observed a significant age-dependent increase in Cx32 protein levels in Tg cohorts compared to age-matched controls (3 months, Fig. 7c, d) as well as young MBP29 Tg mice (Suppl. Figure S9b, Online Resource 12). These results are similar to those in the mouse PD cohorts; however, a significant decrease in Cx32 mRNA in both young and adult Tg MBP29 cohorts compared to non-Tg age-matched controls within the cortex and corpus callosum was clearly observed (Fig. 7e, f). These results are consistent with our in vitro oligodendrocyte results pointing to an overall attempt to downregulate Cx32 in oligodendrocytes following α-syn expression, indicating that Cx32 expression in oligodendrocytes is differentially regulated compared to its neuronal counterpart.

Cx32 interacts with α-syn in PD brains

To further assess the relationship between Cx32 and α-syn in human PD brains, we analyzed the putamen and substantia nigra pars compacta (SNpc) from four neuropathologically diagnosed PD cases and four age-matched controls (Suppl. Table S3, Online Resource 3). While we observed no statistically significant differences in Cx32 expression between PD and control cases within the putamen (Fig. 7g), the SNpc, a region highly vulnerable to PD pathogenesis, showed a marked decrease in Cx32 expression (Fig. 7h). Interestingly and consistent with the decrease in Cx32 within the substantia nigra, we observed no significant differences in the levels of α-syn from control and PD cases from the same region (Suppl. Figure S9c, Online Resource 12). We then assessed the levels of Cx32 in an area outside the nigrostriatal pathway, the Brodmann area 9 (BR9) of the dorsal lateral prefrontal cortex, a region relatively unaffected by α-syn pathology in PD during the early stages of the disease process. In contrast to the substantia nigra, we observed no significant differences in Cx32 protein levels between controls (n = 15) and PD cases (n = 15) (Fig. 7i, j), suggesting that the reduction of Cx32 levels within the nigral region may serve as a protective mechanism to reduce α-syn uptake and accumulation. To further validate the interaction between Cx32 and α-syn in human PD brains, we next immunoprecipitated α-syn from the putamen, the region containing higher levels of Cx32 relative to the SNpc. Cx32 co-immunoprecipitated with α-syn in two out of four PD cases but this interaction was not observed in any of the four age-matched control cases tested (Fig. 7k, Suppl. Figure S9d, Online Resource 12). We next analyzed Cx32 levels from the putamen region of control and pathologically diagnosed MSA cases (Suppl. Table S3, Online Resource 3), a region highly vulnerable to α-syn accumulation in oligodendrocytes of MSA patients [54, 64]. Similar to the substantia nigra in PD, we identified a significant decrease in Cx32 levels in MSA cases compared to age-matched controls (Fig. 7l), further validating a potential relationship between human α-syn and Cx32 in the pathophysiology of PD and MSA.

Discussion

In this study, we demonstrate that Cx32 plays a critical role in facilitating the preferential uptake of α-syn via direct protein–protein interaction in both neurons and oligodendrocytes, the primary cell types highly vulnerable to α-syn accumulation in PD and MSA, respectively. Our findings
Contribute to the current hypothesis on the progression and spreading of neurodegenerative disorders, which highlights the importance of cellular connectivity in the uptake and cell-to-cell transfer of misfolded proteins. It is well-established that cellular communication is enhanced by Cx expression, and while novel functional roles outside of neuronal communication have been identified for other Cxs [19], the functional roles of Cxs in the progression of PD and MSA have remained relatively unexplored. To our knowledge, the current study demonstrates for the first time that Cx32 plays an essential role in the uptake and propagation of α-syn assemblies, and to a lesser extent monomers and fibrillar assemblies. It is important to note that the limited uptake of α-syn fibrils mediated by Cx32 observed in this study may in part be due to the lack of fibril sonication. Sonication not only reduces the overall fibrillar length, but also generates oligomeric α-syn assemblies, and induces unwanted post-translational modifications within the molecule [1, 38]. Therefore, to maintain fibril integrity and avoid a heterogeneous mixture of oligomeric and fibrillar assemblies in our fibrillar preparations, we omitted the sonication step. Given this notion, we are aware that further studies are needed to assess whether fibril sonication might increase the uptake of fragmented fibrillar assemblies by Cx32 [1, 2]. Importantly, while the previous studies have emphasized Cx32 expression within cells of the oligodendrocyte lineage, more recent reports suggest Cx32 expression within multiple neuronal cell types, including those from cortical and dopaminergic regions [17, 49, 50]. Furthermore, single cell RT-PCR analyses validated Cx32 expression within neurons from the locus coeruleus, cortex, hippocampus and substantia nigra, a brain region highly vulnerable to PD pathogenesis [69]. Moreover, Gong and colleagues validated the presence of Cx32 expression within primary cortical neurons using siRNA technology [17]. Taken together, these results validate the expression profile of Cx32 within multiple neuronal cell types.

To further expand these findings, we demonstrate herein that Cx32 is differentially regulated in neurons and oligodendrocytes both in vitro and in animal models of PD (L61, A30P) and MSA (MBP29). Whereas upregulation of Cx32 was observed in human neuronal SH-SY5Y cells exposed to α-syn assemblies or by overexpressing the α-syn gene (SNCA), only exposure to α-syn in naïve oligodendrocytes increased Cx32 expression (albeit to a lesser extent than in neurons). Conversely, expression of α-syn-GFP coupled with α-syn treatment in OPCs led to a significant decrease in Cx32 expression compared to that of wild-type OPC-treated cells. We hypothesize that this may be due to differential regulation of Cx32 within OPCs compared to their neuronal counterpart. Indeed, OPCs overexpressing Cx32-mCherry showed a significant downregulation of Cx32 following α-syn treatment, which we observed to be upregulated in neuronal cells and wild-type OPCs exposed to the same conditions. The downregulation of Cx32 in oligodendrocytes may also be explained by its direct association with oligodendrocyte myelination, as we have previously demonstrated that α-syn expression within oligodendrocytes leads to oligodendrocyte maturation deficits [12]. While the expression pattern of Cx32 as it relates to myelination remains to be determined, gene expression analysis has identified Cx32 expression primarily within myelinating oligodendrocytes [74], suggesting a direct association between Cx32 expression and oligodendrocyte myelination. While the factors that regulate Cx32 expression in neurons and oligodendrocytes remain elusive, we have demonstrated that the increased expression of Cx32 in neurons and oligodendrocytes leads to a selective increase in α-syn uptake compared to that of α-syn monomers or fibrillar assemblies.

Notably, although the levels of α-syn uptake in rat OLN-93 oligodendrocytes were less than those observed in SH-SY5Y cells or human oligodendrocytes, the inability of Cx32 to properly localize to the cellular membrane in OLN-93 cells may, in part, explain this result. For instance, in liver hepatocytes, the cell type with the highest expression of Cx32 outside the central nervous system, Cx32 is localized to the cell soma in immature cells, before it fully translocates to the cellular membrane following hepatocyte maturation [39]. Consistent with this observation, Buckinx and colleagues have reported that OLN-93 oligodendrocytes lack the ability to fully differentiate in vitro and, as such, fail to express the protein markers associated with mature oligodendrocytes [6]. These findings suggest that OLN-93 oligodendrocytes in our culture conditions may not reach full maturation and, as such, may incorrectly compartmentalize Cx32, preventing the interaction between Cx32 and α-syn necessary to facilitate cellular uptake. This hypothesis is consistent with our experimental results using anisomycin, the p38 MAPK activator known to promote Cx32 degradation [39], leading to a significant decrease in α-syn uptake. These results demonstrate that proper localization of Cx32 is necessary to interact with α-syn prior to cellular uptake.

To demonstrate a direct protein–protein interaction between Cx32 and α-syn, and eliminate potential antibody cross-reactivity, we took advantage of our tagged Cx32-mCherry system and developed a co-culture model that allows for direct quantification of α-syn cell-to-cell transfer, a model that is suitable for high content analysis [43]. Using this system, we successfully quantified higher levels of α-syn-GFP puncta in cells expressing Cx32-mCherry relative to the respective controls. Using confocal image analysis, we validated the colocalization between α-syn-GFP oligomers and Cx32-mCherry plaques, indicating that a direct interaction between Cx32 and α-syn is necessary for binding and internalization. Moreover, we demonstrated that α-syn cell-to-cell transfer in human SH-SY5Y cells is enhanced...
by direct cellular connectivity rather than its differentiation state. Nonetheless, the observed increase in oα-syn transfer in differentiated conditions is likely an effect of enhanced cellular connectivity and not due to an elevated α-syn load, as no statistically significant differences were observed in α-syn transfer in the α-syn-GFP/mCherry co-culture model in proliferating vs differentiating conditions. Recently, the viral HIV protein dickkopf-1 (26 kDa) was shown to promote uptake and downstream toxicity by inducing the opening of Cx43 hemichannels [32]. A pore-forming activity for α-syn has been reported [65], suggesting a potential mechanism similar to that seen with dickkopf-1 for α-syn uptake and transfer via Cx32. Nonetheless, it is clear that a direct interaction between oα-syn and Cx32 enhances oα-syn uptake in neurons and oligodendrocytes. Indeed, expanding on previous in vitro results [60], we further demonstrate that IP of oα-syn in differentiated SH-SY5Y cells pulls down Cx32 and that the levels of α-syn correlate with Cx32 upregulation, pinpointing a direct relationship between Cx32 and α-syn. These results suggest that oα-syn uptake is mediated, at least in part, via a protein–protein interaction, and not due to non-specific membrane binding or Cx32-dependent channel diffusion, as we have shown this mechanism to be energy-dependent. Our work highlights the role of Cx proteins and neuronal connectivity during misfolded protein uptake and transfer, which we believe may extend to other neurodegenerative disorders beyond PD and related synucleinopathies which includes AD as shown by the uptake of oAβ assemblies mediated by Cx32.

In an attempt to block cellular α-syn uptake, we used well-known Cx32 peptide mimetics that bind and inhibit Cx32 hemichannel activity (Gap3211 and Gap2409). While we observed a partial inhibition of oα-syn uptake in neurons and oligodendrocytes, this effect did not translate to fibrillar assemblies. In contrast to these results, the use of gap junction inhibitors (CBX, MQ and 2-APB) successfully blocked soluble and insoluble (fibrillar) α-syn uptake in both neurons and oligodendrocytes. The lack of fibrillar uptake inhibition by peptide mimetics may in part be explained by the high affinity of fibrillar α-syn assemblies to cellular membranes [18], the selective binding of Cx32 to α-syn, the limited efficacy of the Cx32 peptide sequences used (which may not target the region interest) and/or the half-life of the peptides within the cells. However, other mechanisms cannot be ruled out including an unidentified Cx that may be involved in the preferential uptake of fibrillar α-syn assemblies. The recent identification of LAG-3, a specific receptor for the uptake and transmission of α-syn fibrils, suggest different mechanisms of uptake between oligomeric and fibrillar assemblies [29]. However, oligodendrocytes lack LAG-3 expression [29] and, therefore, the involvement of other Cx proteins in the selective uptake of different α-syn assemblies remains plausible. Collectively, these results indicate that pharmacological strategies may be more effective than peptide mimetics at blocking the uptake of oligomeric and fibrillar assemblies in neurons and oligodendrocytes via a Cx32-dependent mechanism.

The accumulation of α-syn pathology and subsequent propagation in PD and MSA, as well as corresponding animal models of these disorders, display a clear age-dependent association. Thus, the observed increase in Cx32 protein levels between adult and aged Tg PD models (L61, A30P), as well as those modeling MSA (MBP29), are consistent with the increase in α-syn pathology within vulnerable brain regions of these mice over time [22, 46]. However, further studies are needed to assess whether the familial A30P mutation, given its lower affinity for cellular membranes [66], exacerbates Cx32 expression compared to its wild-type counterpart. Furthermore, the binding affinities of A30P and other familial α-syn mutations to Cx32 and/or their ability to promote Cx32 upregulation compared to wild-type α-syn remains to be determined. Nonetheless, all PD and MSA animal models assessed in this study displayed an age-dependent upregulation of Cx32 which is likely due to the increased α-syn accumulation in the brain parenchyma, directly implicating Cx32 in the pathophysiology of PD and MSA. In human brains, however, a significant decrease in Cx32 levels within the substantia nigra and the putamen region of PD and MSA cases, respectively, was clearly observed. Although the reasons for the decrease in Cx32 levels within the primary regions affected by PD (substantia nigra) or MSA (putamen) remain relatively unknown, the discrepancy between the cellular and animal models compared to human PD may be explained by multiple factors, including the degree of α-syn pathology and/or the region associated with α-syn vulnerability, coupled to cell loss within affected brain regions [54, 64]. Indeed, we analyzed a region relatively unaffected by α-syn accumulation during the early stages of the disease process (the BR9 cortical region) in both control and PD cases and observed no significant changes in Cx32 expression. Therefore, it is plausible that the reduction in Cx32 levels may be a cellular attempt to reduce α-syn accumulation in regions with high α-syn burden as demonstrated by our human oligodendrocyte model system. Thus, the regions that lose Cx32 in response to PD or MSA (e.g., substantia nigra or putamen, respectively) may be more vulnerable to cell death due to the accumulation of α-syn pathology. Interestingly, increased Cx32 expression has been demonstrated to promote cellular apoptosis [68], suggesting that, in addition to increasing cellular connectivity and modulating α-syn uptake, Cx32 may have other non-canonical functions that remain to be fully elucidated. Moreover, given that we identified a direct interaction between Cx32 and α-syn in PD, but not in control cases, suggests the possibility that Cx32 may associate within different α-syn assemblies (SDS-insoluble) during...
the aggregation process in PD. Alternatively, it is possible that the expression profile of non-neuronal cell types (which differentially regulate Cx32 expression in pathological state) may mask the true expression of Cx32 in neurons in PD and MSA. Therefore, we hypothesize that Cx32 upregulation may first occur during the early stages of the disease as shown for other Cx in different neurodegenerative diseases [49], followed by a downregulation in late stages as a protective mechanism to reduce the uptake and accumulation of α-syn pathology; however, additional studies are needed to validate this hypothesis.

To date, multiple model systems have been developed to assess the uptake and transmission of different α-syn assemblies in vitro and in vivo [41, 42, 45]. Recently, Fortuna and colleagues demonstrated that intra-cerebroventricular injection of α-syn assemblies in non-Tg wild-type mice is able to induce the PD-associated motor and non-motor symptoms that were previously demonstrated following striatal injection of fibrillar α-syn assemblies [14, 28, 52, 53]. While the changes in the Cx expression in these transmission models of α-syn assemblies have yet to be investigated, we hypothesize that Cx32 plays a major role in this process and may contribute and/or dictate the direction and/or cell-type vulnerability of α-syn spreading from one region to another. Although the role of Cx32 upregulation as a result of α-syn accumulation remains elusive, we further hypothesize that Cx32 in neurons plays a role in the bystander effect associated with the spread of toxic signals, as reported for other Cxs in critical brain regions in other neurodegenerative disorders [49]. For instance, Cx43 upregulation was demonstrated within the caudate nucleus in Huntington’s disease (HD) and within the cortex in AD [30, 72]. Moreover, in cultured astrocytes, Cx43 appears to be upregulated following αβ treatment [33]. However, a similar role for Cx43 in neurons was not identified but, a different, unidentified Cx has been hypothesized to play a similar role [33]. In global ischemia, vulnerable neurons of the CA1 region were found to increase Cx32 and Cx36 expression, whereas no changes in the CA3 region were observed, suggesting vulnerable regional specificity associated with Cx upregulation in the disease state [31]. Taken together, our results show a novel mechanism selective for the uptake and propagation of α-syn assemblies mediated by Cx32. Moreover, we demonstrate that Cx32 is a suitable therapeutic candidate for pharmacological intervention to impede the uptake and propagation of α-syn assemblies in PD and MSA.

Acknowledgements We thank Emelie Severinsson and Serge Mudio for technical assistance; Livia Civitelli for performing SEC and preparing the primary neurons; Joakim Bergström, Sara Ekmark-Lewén and Astrid Gumucio for help with the transgenic mice (A30P); Philipp Kahle and Eliezer Masliah for generating and providing the A30P and MBP29 mice, respectively; and Maria Ntzoumi and Vesa Loitto from the EM and imaging facilities at Linköping University for technical assistance. We thank the Swedish Research Council (MH: 523-2013-2735), The Swedish Brain foundation, The Research Foundation of the Swedish Parkinson’s Disease Association, the Östergötland Research Foundation for Parkinson’s Disease (JFR and MH), the Parkinson Research Foundation, the Swedish Alzheimer’s Foundation (JFR and MH), The Ahlén Foundation (JFR), the Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research, Gustav V and Queen Victoria’s Foundation, the Swedish Dementia Foundation, the Mariann and Marcus Wallenberg Foundation, the Linköping University Neurobiology Centre (JFR) and the County Council of Östergötland (JFR and MH), and the Parkinson’s and Movement Disorder Foundation (JFR). AH is a graduate student of the research training group 2162 “Neurodevelopment and Vulnerability of the Central Nervous System” of the Deutsche Forschungsgemeinschaft (DFG GRK2162), JW is members of research training group 2162 of the Deutsche Forschungsgemeinschaft (DFG GRK2162). The funding agencies were not involved in the design or interpretation of the study.

Author contributions JFR designed and performed the study and wrote the first draft of the manuscript. CS performed the neuronal RT-PCR experiments. JFR and MH analyzed the results. PS supervised the human neuropathological studies. MI supervised the A30P animal studies. AH and JW performed the experiments with human MSA samples and MBP29 animals. All authors were involved in the discussion of the results and editing the manuscript.

Compliance with ethical standards

Conflict of interest All authors declare no conflicts of interest.

Ethical approval All procedures were performed according to the European (2010/63/EU) and NIH Guide for the Care and Use of Experimental Animals and approved by Uppsala University or the University Hospital Erlangen Animal Care and Use Committee. Human brain samples (control and PD cases) were obtained from the Karolinska Institute (KI) or the Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam (open access: http://www.brainbank.nl) (MSA and controls) and approved by the ethics review board committee at KI and the Netherlands Brain Bank, Amsterdam.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Abdelmotilib H, Maltbie T, Delic V, Liu Z, Hu X, Fraser KB et al (2017) alpha-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic neurodegeneration. Neurobiol Dis 105:84–98. https://doi.org/10.1016/j.nbd.2017.05.014
2. Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M (2010) An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 20:1069–1082. https://doi.org/10.3233/jad-2010-091363
3. Angot E, Steiner JA, Hansen C, Li JY, Brundin P (2010) Are synucleinopathies prion-like disorders? Lancet Neurol 9:1128–1138. https://doi.org/10.1016/s1474-4422(10)70213-1
4. Bennett MV, Barrio LC, Bargiello TA, Spray DC, Hertzberg E, Saez JC (1991) Gap junctions: new tools, new answers, new questions. Neuron 6:305–320
5. Bruzzone R, White TW, Paul DL (1996) Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem 238:1–27
6. Buckinx R, Smolders I, Sahebali S, Janssen D, Smets I, Ameloot M et al (2009) Morphological changes do not reflect biochemical and functional differentiation in OLN-93 oligodendroglial cells. J Neurosci Methods 184:1–9. https://doi.org/10.1016/j.jneumeth.2009.07.004
7. Choi YR, Cha SH, Kang SJ, Kim JB, Jou I, Park SM (2018) Prion-like propagation of alpha-synuclein is regulated by the FcgammaRIIB-SHP-1/2 signaling pathway in neurons. Cell Rep 22:136–148. https://doi.org/10.1016/j.celrep.2017.12.009
8. Dawson VL, Dawson TM, Uhl GR, Snyder SH (1993) Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 90:3256–3259
9. De Vuyst E, Decrock E, Cabooter L, Dubyak GR, Naus CC, Dottin P, Gassot M et al (2010) Intracellular calcium changes trigger connexin 32 hemichannel opening. EMBO J 25:34–44. https://doi.org/10.1038/sj.emboj.7600908
10. Dehay B (2014) Evidence piles up for prion-like propagation mechanisms in synucleinopathies. Mov Disord 29:187. https://doi.org/10.1002/mds.25793
11. Domert J, Rao SB, Agholme L, Broorsen AC, Marcusson J, Hallbeck M et al (2014) Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis 65:82–92. https://doi.org/10.1016/j.nbd.2013.12.019
12. Ettle B, Kerman BE, Valera E, Gillmann C, Schlachetzki JC, Reiprich S et al (2016) alpha-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. Acta Neuropathol 132:59–75. https://doi.org/10.1007/s00401-016-1572-y
13. Eugenin EA, Gonzalez H, Saez CG, Saez JC (1998) Gap junctional communication coordinates vasopressin-induced glycogenolysis in rat hepatocytes. Am J Physiol 274:G1109–G1116
14. Fortuna JTS, Gralle M, Beckman D, Neves FS, Diniz LP, Frost PS et al (2017) Brain infusion of alpha-synuclein oligomers induces motor and non-motor Parkinson’s disease-like symptoms in mice. Behav Brain Res 353:150–160. https://doi.org/10.1016/j.bbr.2017.06.047
15. Gasser T (2005) Genetics of Parkinson’s disease. Curr Opin Neurol 18:363–369
16. Goedert M, Falcon B, Clavaguera F, Tolnay M (2014) Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep 14:495. https://doi.org/10.1007/s11910-014-0495-z
17. Gong G, Yuan L, Cai L, Ran M, Zhang Y, Gong H et al (2014) Tetramethylpyrazine suppresses transient oxygen-glucose deprivation-induced connexin32 expression and cell apoptosis via the ERK1/2 and p38 MAPK pathway in cultured hippocampal neurons. PLoS ONE 9:e105944. https://doi.org/10.1371/journ al.pone.0105944
18. Gorbenko G, Trusova V, Girych M, Adachi E, Mizuguchi C, Saito H (2015) Interactions of lipid membranes with fibrillar protein aggregates. Adv Exp Med Biol 855:135–155. https://doi.org/10.1007/978-3-319-17344-3_6
19. Huckstep RT, Id Bihi R, Eason R, Spyer KM, Dicke N, Willecke K et al (2010) Connexin hemichannel-mediated CO2-dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity. J Physiol 588:3901–3920. https://doi.org/10.1113/jphysiol.2010.192088
20. Ingelsson M (2016) Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other Lewy body disorders. Front Neurol 10:408. https://doi.org/10.3389/fneuro .2016.00408
21. Juszczak GR, Swiergier AH (2009) Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 33:181–198. https://doi.org/10.1016/j.pnpbp.2008.12.014
22. Kahle PJ (2008) alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 115:87–95. https://doi.org/10.1007/s0040 1-008-0302-x
23. Kahle PJ, Neumann M, Ormen L, Muller V, Jacobsen H, Schindzielorz A et al (2000) Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20:6365–6373
24. Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK (2016) Autosomal dominant Parkinson’s disease caused by SNCA duplications. Parkinsonism Relat Disord 22(Suppl 1):S1–S6. https://doi.org/10.1016/j.parkreldis.2015.09.007
25. Kordower JH, Brundin P (2009) Lewy body pathology in long-term fetal nigral transplants: is Parkinson’s disease transmitted from one neural system to another? Neuropsychopharmacology 34:254. https://doi.org/10.1038/npp.2008.161
26. Lazarov DF, Pavlou MAS, Outeiro TF (2017) Cellular models as tools for the study of the role of alpha-synuclein in Parkinson’s disease. Exp Neurol 298:162–171. https://doi.org/10.1016/j.expne urol.2017.05.007
27. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503. https://doi.org/10.1038/nm1746
28. Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209:975–986. https://doi.org/10.1084/jem.20112457
29. Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y et al (2016) Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. https://doi.org/10.1126/science.aad3374
30. Nagy JI, Li W, Hertzberg EL, Marotta CA (1996) Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer’s disease. Brain Res 717:173–178
31. Oguro K, Jover T, Tanaka H, Lin Y, Kojima T, Oguro N et al (2001) Global ischemia-induced increases in the gap junctional proteins connexin 32 (Cx32) and Cx36 in hippocampus and enhanced vulnerability of Cx32 knock-out mice. J Neurosci 21:7534–7542
32. Orellana JA, Saez JC, Bennett MV, Berman JW, Morgello S, Eugenin EA (2014) HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism. J Neurochem 128:752–763. https://doi.org/10.1111/jnc.12492
33. Orellana JA, Shoji KF, Abudara V, Ezan P, Amigou E, Saenz PJ et al (2011) Amyloid beta-induced death in neurons involves glial and neuronal hemichannels. J Neurosci 31:4962–4977. https://doi.org/10.1523/jneurosci.6417-10.2011
34. Patterson KR, Remmers C, Fu Y, Broker S, Kanaan NM, Vana L et al (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem 286:23063–23076. https://doi.org/10.1074/jbc.m111.237974
35. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M et al (2015) alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522:340–344. https://doi.org/10.1038/nature14547
36. Petrucci S, Ginevino M, Valente EM (2016) Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models. Parkinsonism Relat Disord 22(Suppl 1):S16–S20. https://doi.org/10.1016/j.parkreldis.2015.08.015

37. Pfefkerkorn CM, Jiang Z, Lee JC (2012) Biophysics of alpha-synuclein membrane interactions. Biochim Biophys Acta 1818:162–171. https://doi.org/10.1016/j.bbapap.2011.07.032

38. Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM et al (2018) Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson’s disease in rodents. J Parkinsons Dis 8:303–322. https://doi.org/10.3233/jpd-171248

39. Qin J, Chang M, Wang S, Liu Z, Zhu W, Wang Y et al (2016) Connexin 32-mediated cell-cell communication is essential for hepatic differentiation from human embryonic stem cells. Sci Rep 6:37388. https://doi.org/10.1038/srep37388

40. Ray A, Katoch P, Jain N, Mehta PP (2018) Dileucine-like motifs in the C-terminal tail of connexin32 control its endocytosis and assembly into gap junctions. J Cell Sci. https://doi.org/10.1242/jcs.207340

41. Rey NL, Petit GH, Bousset L, Melki R, Brundin P (2013) Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126:555–573. https://doi.org/10.1007/s00401-013-1160-3

42. Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ et al (2016) Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med 213:1759–1778. https://doi.org/10.1084/jem.20160368

43. Reyes JF, Olsson TT, Lamberts JT, Devine MJ, Kunath T, Brundin P (2015) A cell culture model for monitoring alpha-synuclein cell-to-cell transfer. Neurobiol Dis 77:266–275. https://doi.org/10.1016/j.nd.2014.07.003

44. Reyes JF, Rey NL, Angot E (2013) Transmission of tau pathology induced by synthetic preformed tau filaments. J Neurosci 33:6707–6708. https://doi.org/10.1523/jneurosci.0725-13.2013

45. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E (2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 62:387–398. https://doi.org/10.1002/glia.22611

46. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I et al (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568–578. https://doi.org/10.1002/jnr.10231

47. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezdor E et al (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139. https://doi.org/10.1016/s1474-4220(09)70293-5

48. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl):S10–S17. https://doi.org/10.1038/nm1066

49. Rouach N, Avignone E, Meme W, Koulaoff A, Venance L, Blomstrand F et al (2002) Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 94:457–475

50. Rozental R, Giaume C, Spray DC (2000) Gap junctions in the nervous system. Brain Res Brain Res Rev 32:11–15

51. Rutherford NJ, Brooks M, Giasson BI (2016) Novel antibodies to phosphorylated alpha-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes. Acta Neuropathol Commun 4:80. https://doi.org/10.1186/s40478-016-0357-9

52. Sacino AN, Ayers JJ, Brooks MM, Chakrabarty P, Hudson VJ 3rd, Howard JK et al (2016) Non-prion-type transmission in A53T alpha-synuclein transgenic mice: a normal component of spinal homogenates from naive non-transgenic mice induces robust alpha-synuclein pathology. Acta Neuropathol 131:151–154. https://doi.org/10.1007/s00401-015-1505-1

53. Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE et al (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, glosis, and a neuronal injury marker. J Neurosci 34:12368–12378. https://doi.org/10.1523/jneurosci.2102-14.2014

54. Sako W, Murakami N, Izumi Y, Kaji R (2014) The difference in putamen volume between MSA and PD: evidence from a meta-analysis. Parkinsonism Relat Disord 20:873–877. https://doi.org/10.1016/j.parkreldis.2014.04.028

55. Sardar Sinha M, Ansell-Schultz A, Civitelli L, Hildesjo C, Larson M, Lannfelt L et al (2018) Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathol 136:41–56. https://doi.org/10.1007/s00404-018-1868-1

56. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G et al (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25:10689–10699. https://doi.org/10.1523/jneurosci.3527-05.2005

57. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208

58. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473

59. Stauffer KA (1995) The gap junction proteins beta 1-connexin (connexin-32) and beta 2-connexin (connexin-26) can form heteromeric hemichannels. J Biol Chem 270:6768–6772

60. Sung JY, Lee HJ, Jeong EI, Oh Y, Park J, Kang KS et al (2007) Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells. Neurosci Lett 416:289–293. https://doi.org/10.1016/j.neulet.2007.02.025

61. Tanaka T, Yamasaki H, Mselid M (2001) Induction of a bystander effect in HeLa cells by using a biconic vector carrying viral thymidine kinase and connexin32 genes. Mol Carcinog 30:176–180

62. Tank J, da Costa-Goncalves AC, Kamer I, Qadri F, Ubhi K, Rockenstein E et al (2014) Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha-synuclein in oligodendrocytes. Physiol Rep. https://doi.org/10.14814/phy2.12209

63. Tao L, Harris AL (2007) 2-Aminoethoxydiphenyl borate directly inhibits channels composed of connexin26 and/or connexin32. Mol Pharmacol 71:570–579. https://doi.org/10.1124/mol.106.027508

64. Tong J, Wong H, Guttmann M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson’s disease and progressive supranuclear palsy: a comparative investigation. Brain 133:172–188. https://doi.org/10.1093/brain/awp282

65. Tosatto L, Andrighetti AO, Plotnegher N, Antonini V, Tessari T, Blomstrand F et al (2002) Gap junctions and connexin32. Mol Pharmacol 71:570–579. https://doi.org/10.1124/mol.106.027508

66. Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wraisdlo W, Oerck C, Gonzalez T, Trejo M, Spencer B, Kosberg W (2011) Connexin32 pore forming activity upon membrane association. Biochim Biophys Acta 1818:2876–2883. https://doi.org/10.1016/j.bbapap.2012.07.007

67. Tsigenly JF, Sharikov Y, Koznetsova VL, Greenberg JP, Wrasidlo W, Oerck C, Gonzalez T, Trejo M, Spencer B, Kosberg W, Kasah Y (2015) Molecular determinants of alpha-synuclein mutants’ oligomerization and membrane interactions. ACS Chem Neurosci 6:403–416. https://doi.org/10.1021/nc500332w
67. Ubhi K, Low P, Masliah E (2011) Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 34:581–590. https://doi.org/10.1016/j.tins.2011.08.003

68. Udawatte C, Ripps H (2005) The spread of apoptosis through gap-junctional channels in BHK cells transfected with Cx32. Apoptosis 10:1019–1029. https://doi.org/10.1007/s10495-005-0776-8

69. Vandecasteele M, Glowinski J, Venance L (2006) Connexin mRNA expression in single dopaminergic neurons of substantia nigra pars compacta. Neurosci Res 56:419–426. https://doi.org/10.1016/j.neures.2006.08.013

70. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA 110:19555–19560. https://doi.org/10.1073/pnas.1318268110

71. White TW, Bruzzone R (1996) Multiple connexin proteins in single intercellular channels: connexin compatibility and functional consequences. J Bioenerg Biomembr 28:339–350

72. Vis JC, Nicholson LF, Faull RL, Evans WH, Severs NJ, Green CR (1998) Connexin expression in Huntington’s diseased human brain. Cell Biol Int 22:837–847. https://doi.org/10.1006/cbir.1998.0388

73. Xicoy H, Wieringa B, Martens GJ (2017) The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. Mol Neurodegener 12:10. https://doi.org/10.1186/s13024-017-0149-0

74. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929–11947. https://doi.org/10.1523/jneurosci.1860-14.2014

75. Zhou JZ, Jiang JX (2014) Gap junction and hemichannel-independent actions of connexins on cell and tissue functions—an update. FEBS Lett 588:1186–1192. https://doi.org/10.1016/j.febslet.2014.01.001

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.